- Home
- TENX vs LEXX Comparison
TENX vs LEXX Comparison
Compare TENX & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- LEXX
- Stock Information
- Founded
- TENX 1967
- LEXX 2004
- Country
- TENX United States
- LEXX Canada
- Employees
- TENX N/A
- LEXX N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- TENX Health Care
- LEXX Health Care
- Exchange
- TENX Nasdaq
- LEXX Nasdaq
- Market Cap
- TENX 21.6M
- LEXX 20.9M
- IPO Year
- TENX N/A
- LEXX N/A
- Fundamental
- Price
- TENX $6.06
- LEXX $0.99
- Analyst Decision
- TENX Strong Buy
- LEXX Strong Buy
- Analyst Count
- TENX 3
- LEXX 1
- Target Price
- TENX $16.00
- LEXX $7.00
- AVG Volume (30 Days)
- TENX 11.9K
- LEXX 73.8K
- Earning Date
- TENX 05-14-2025
- LEXX 07-11-2025
- Dividend Yield
- TENX N/A
- LEXX N/A
- EPS Growth
- TENX N/A
- LEXX N/A
- EPS
- TENX N/A
- LEXX N/A
- Revenue
- TENX N/A
- LEXX $525,923.00
- Revenue This Year
- TENX N/A
- LEXX $0.62
- Revenue Next Year
- TENX N/A
- LEXX $14.19
- P/E Ratio
- TENX N/A
- LEXX N/A
- Revenue Growth
- TENX N/A
- LEXX 29.95
- 52 Week Low
- TENX $2.77
- LEXX $0.92
- 52 Week High
- TENX $7.89
- LEXX $4.38
- Technical
- Relative Strength Index (RSI)
- TENX 55.80
- LEXX 41.00
- Support Level
- TENX $5.60
- LEXX $0.92
- Resistance Level
- TENX $6.31
- LEXX $1.05
- Average True Range (ATR)
- TENX 0.27
- LEXX 0.06
- MACD
- TENX -0.01
- LEXX 0.01
- Stochastic Oscillator
- TENX 63.31
- LEXX 32.16
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.